Go to Header
Go to Navigation
Go to Content
Go to Footer
Login
Help
中文（繁體）
Research Resources
CUHK UPDates
Theses
Experts List
User Guides
About Us
List of Researchers
> Professor Buig Yue Brigette MA
Home
Research Outputs
Researcher Profiles
Department Profiles
Research Areas
Professor MA Buig Yue Brigette
Personal Information
Position and Department
Professor
,
Department of Clinical Oncology
ORCiD
0000-0003-4802-1102
CUHK Research Outputs
1 of 8
Abstract 3170: Epigenetic identification and functional characterization of a novel RING finger protein tumor suppressor in nasopharyngeal carcinoma and esophageal carcinoma
(
2024
)
Clinical Management of Gastrointestinal and Liver Toxicities of Immune Checkpoint Inhibitors
(
2024
)
Early detection of nasopharyngeal carcinoma: performance of a short contrast-free screening magnetic resonance imaging
(
2024
)
Radiologic extranodal extension for nodal staging in nasopharyngeal carcinoma
(
2024
)
Synthetic BZLF1-targeted transcriptional activator for efficient lytic induction therapy against EBV-associated epithelial cancers
(
2024
)
A novel tumor suppressor encoded by a 1p36.3 lncRNA functions as a phosphoinositide-binding protein repressing AKT phosphorylation/activation and promoting autophagy
(
2023
)
A phase Ib/II study of nanatinostat (Nstat) plus valganciclovir (VGCV) in EBV+ solid tumors and with pembrolizumab (PEM) in recurrent/metastatic nasopharyngeal carcinoma (R/M NPC)
(
2023
)
Artificial intelligence-powered spatial analysis of tumor microenvironment (TME) in nasopharyngeal carcinoma (NPC) patients treated with immune checkpoint inhibitors (ICI)
(
2023
)
Cancer-associated fibroblasts potentiate colorectal cancer progression by crosstalk of the IGF2–IGF1R and Hippo–YAP1 signaling pathways
(
2023
)
Cancer of the Nasopharynx
(
2023
)
Fragmentation landscape of cell-free DNA revealed by deconvolutional analysis of end motifs
(
2023
)
Frequency of Peripheral CD8+ T Cells Expressing Chemo-Attractant Receptors CCR1, 4 and 5 Increases in NPC Patients with EBV Clearance upon Radiotherapy
(
2023
)
Hot on the trail in the TME: Clues from a trilogy of checkpoint inhibitor trials in nasopharyngeal cancer
(
2023
)
Immunotherapy for Head and Neck Cancer
(
2023
)
MD Anderson Cancer Center global precision oncology decision support (Glo-PODS) clinical trial genomic support: Pilot program at the Prince of Wales Hospital (Chinese University of Hong Kong - CUHK)
(
2023
)
NEOSPACE trial: Neoadjuvant pembrolizumab-gemcitabine-cisplatin followed by concurrent pembrolizumab-chemoradiation and maintenance pembrolizumab for stage IVA nasopharyngeal cancer (NPC)
(
2023
)
Plasma Epstein–Barr Virus DNA and Risk of Future Nasopharyngeal Cancer
(
2023
)
Preclinical evaluation of the VEGF/Ang2 bispecific nanobody BI 836880 in nasopharyngeal carcinoma models
(
2023
)
Recommendations for Epstein-Barr virus-based screening for nasopharyngeal cancer in high- and intermediate-risk regions
(
2023
)
Safety and clinical activity of atezolizumab plus erlotinib in patients with non-small-cell lung cancer
(
2023
)
Transcriptomics of Epstein-Barr virus aids to the classification of T-cell evasion in nasopharyngeal carcinoma
(
2023
)
TWT-101: A First-In-Clinic Study of CFI-402411, a Hematopoietic Progenitor Kinase-1 (HPK1) Inhibitor, as Single Agent or Combined With Pembrolizumab in Subjects With Advanced Solid Malignancies
(
2023
)
A phase 1b/2 study of nanatinostat and valganciclovir in patients with advanced Epstein-Barr virus positive (EBV+) solid tumors and in combination with pembrolizumab in patients with recurrent/metastatic nasopharyngeal carcinoma (RM-NPC)
(
2022
)
Characteristics, Treatment and Survival Outcomes of Brain Metastases from Colorectal Cancer [poster presentation]
(
2022
)
Clinical applications of circulating tumor-derived DNA in the management of gastrointestinal cancers – current evidence and future directions
(
2022
)
CpG methylation as epigenetic biomarkers for nasopharyngeal carcinoma diagnostics
(
2022
)
Fangchinoline inhibits non-small cell lung cancer metastasis by reversing epithelial-mesenchymal transition and suppressing the cytosolic ROS-related Akt-mTOR signaling pathway
(
2022
)
Immunotherapy in Recurrent and Metastatic Nasopharyngeal Carcinoma
(
2022
)
Impact of the evolution in RAS mutation analysis in Australian patients with metastatic colorectal cancer
(
2022
)
Improved risk stratification of nasopharyngeal cancer by targeted sequencing of Epstein–Barr virus DNA in post-treatment plasma
(
2022
)
Informing Treatment Decisions In Metastatic Colorectal Cancer Using Conditional Survival Estimates Derived From a Clinical Registry
(
2022
)
Long-term survival outcomes following resection of lung metastases (LM) from a colorectal primary
(
2022
)
MCM6 is a critical transcriptional target of YAP to promote gastric tumorigenesis and serves as a therapeutic target
(
2022
)
Opportunities and challenges in combining immunotherapy and radiotherapy in head and neck cancers
(
2022
)
Outcomes from repeat resection in colorectal cancer patients with liver only metastases
(
2022
)
Prognostic implication of the neoadjuvant rectal score and other biomarkers of clinical outcome in Hong Kong Chinese patients with locally advanced rectal cancer undergoing neoadjuvant chemoradiotherapy
(
2022
)
Prognostic value of cervical nodal necrosis on staging imaging of nasopharyngeal carcinoma in era of intensity-modulated radiotherapy: a systematic review and meta-analysis
(
2022
)
Total Neoadjuvant Therapy for High Risk Rectal Cancer in Western and Asian Populations – Current Evidence and Clinical Applications
(
2022
)
Trends over time in patient characteristics, treatment and outcomes for oligometastatic colorectal cancer involving liver or lung
(
2022
)
A convolutional neural network combined with positional and textural attention for the fully automatic delineation of primary nasopharyngeal carcinoma on non-contrast-enhanced MRI
(
2021
)
BRAFV600E Mutations Arising from a Left-Side Primary in Metastatic Colorectal Cancer: Are They a Distinct Subset?
(
2021
)
Chemotherapy in Combination With Radiotherapy for Definitive-Intent Treatment of Stage II-IVA Nasopharyngeal Carcinoma: CSCO and ASCO Guideline
(
2021
)
Commissioned Programme on the CUHK Phase 1 Clinical Trial Centre at the Prince of Wales Hospital
(
2021
)
Convolutional neural network for discriminating nasopharyngeal carcinoma and benign hyperplasia on MRI
(
2021
)
Dynamic Changes of Post-Radiotherapy Plasma Epstein-Barr Virus DNA in a Randomized Trial of Adjuvant Chemotherapy Versus Observation in Nasopharyngeal Cancer
(
2021
)
Global Implementation of Precision Oncology
(
2021
)
Nasopharyngeal Carcinoma: An Evolving Paradigm
(
2021
)
NPC patients with post-RT EBV clearance show a higher frequency of peripheral CD8 T-cells expressing chemo-attractant receptors at baseline and during radiation therapy
(
2021
)
Overcoming the impact of the COVID-19 pandemic on oncology early phase trials and drug development in Asia-Experiences and perspectives of the Asian Oncology Early Phase 1 Consortium
(
2021
)
Phase I/II study of MAK683 in patients (pts) with advanced malignancies including epithelioid sarcoma
(
2021
)
Most Relevant Area
Oncology
(
Internal medicine related
)
Share Link
Last updated on 2024-03-09 at 16:09
Share Link
Your name*
Your email*
Recipient's name*
Recipient's email*
Message
Auxilliary Information
No information will be stored or shared with any third party.
Cancel
Our policy towards the use of cookies
All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
Ok to Continue
Cookie Policy
